A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerability, and efficacy of 4 weeks of treatment with AP1189 in early rheumatoid arthritis (RA) patients with active joint disease
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Resomelagon (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms BEGIN; SynAct-CS002
- Sponsors Synact Pharma
Most Recent Events
- 14 Nov 2022 Primary endpoint (Change in CDAI), has been met, as per results presented at the ACR Convergence 2022.
- 14 Nov 2022 Results assessing the safety, tolerability and efficacy of AP1189 in early rheumatoid arthritis patients with active joint disease, presented at the ACR Convergence 2022.
- 26 Nov 2021 Status changed from active, no longer recruiting to completed.